The stock of Kamada Ltd (NASDAQ:KMDA) is a huge mover today! About 88,078 shares traded hands or 192.35% up from the average. Kamada Ltd (NASDAQ:KMDA) has risen 35.28% since March 3, 2016 and is uptrending. It has outperformed by 26.93% the S&P500.
The move comes after 9 months positive chart setup for the $185.74M company. It was reported on Oct, 6 by Barchart.com. We have $6.92 PT which if reached, will make NASDAQ:KMDA worth $55.72M more.
Analysts await Kamada Ltd (NASDAQ:KMDA) to report earnings on November, 8. They expect $-0.03 EPS, up 76.92% or $0.10 from last year’s $-0.13 per share. After $-0.04 actual EPS reported by Kamada Ltd for the previous quarter, Wall Street now forecasts -25.00% EPS growth.
According to Zacks Investment Research, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel.”
More notable recent Kamada Ltd (NASDAQ:KMDA) news were published by: Seekingalpha.com which released: “Kamada and Shire extend Glassia supply agreement through 2020” on October 06, 2016, also Businesswire.com with their article: “Kamada Announces Third Extension of Strategic Agreement with Baxalta” published on October 16, 2015, Benzinga.com published: “Kamada’s Phase 2 Trial On Inhaled Alpha-1 Antitrypsin Meets Primary Endpoint” on August 30, 2016. More interesting news about Kamada Ltd (NASDAQ:KMDA) were released by: Businesswire.com and their article: “Kamada Announces Publication in Pediatric Diabetes” published on July 06, 2015 as well as Benzinga.com‘s news article titled: “H.C. Wainwright Talks Kamada’s Recent Phase 2 Results” with publication date: September 01, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.